Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE).
Despite its obvious benefits, many physicians are reluctant to prescribe HRT to patients with SLE. We have performed a retrospective study in 60 postmenopausal women with SLE including 30 HRT users and 30 never users. The patients were studied for 12 months after the initiation of HRT. The two groups were well matched for disease characteristics. The HRT users experienced significant improvements in general well being, libido and depression. There was no significant difference in any other parameter measured. There was no increase in the number of thrombo-embolic events in the user group despite 7 patients having a positive thrombophilia screen. In conclusion, in stable postmenopausal SLE HRT appears well tolerated and safe.
Arden
N K
NK
Department of Rheumatology, St. Thomas' Hospital, London, UK.
Lloyd
M E
ME
Spector
T D
TD
Hughes
G R
GR
D000328:Adult; D003625:Data Collection; D004361:Drug Tolerance; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008875:Middle Aged; D012189:Retrospective Studies; D012449:Safety; D011795:Surveys and Questionnaires; D013923:Thromboembolism / Q000209:etiology